Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Kristi McIntyre, Joyce O'Shaughnessy, Lee Schwartzberg, Stefan Glück, Erhan Berrak, James X. Song, David Cox, Linda T. Vahdat

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This phase 2 study evaluated efficacy and safety of eribulin as first-line therapy for human epidermal growth factor receptor 2-negative (HER2-negative) MBC. Patients with measurable HER2-negative locally recurrent breast cancer or MBC with ≥12 months since prior neoadjuvant or adjuvant (neo/adjuvant) chemotherapy received eribulin mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week cycle. Endpoints included objective response rate (ORR) per RECIST v1.1 (primary), safety, progression-free survival (PFS), clinical benefit rate (ORR + stable disease ≥6 months; CBR), and duration of response (DOR). Fifty-six patients were enrolled and received eribulin; 38 (68 %) had prior neo/adjuvant therapy, including 33 who had anthracycline and/or taxane-containing chemotherapy; 41 (73 %) had estrogen receptor-positive disease, and 12 (21 %) had estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) disease. Patients received a median of 7 cycles (range 1-43); 6 (11 %) received treatment for ≥12 months. ORR was 29 % (95 % CI 17.3-42.2), CBR was 52 %, and median DOR was 5.8 months. Median PFS was 6.8 months. Thirty-six patients (64 %) had grade 3/4 treatment-related adverse events; most common were neutropenia (50 %), leukopenia (21 %), and peripheral neuropathy (21 %). These results demonstrate that eribulin has substantial antitumor activity as first-line treatment for HER2-negative MBC with acceptable safety.

Original languageEnglish
Pages (from-to)321-328
Number of pages8
JournalBreast Cancer Research and Treatment
Volume146
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

eribulin
Breast Neoplasms
Anthracyclines
Safety
Estrogen Receptors
Disease-Free Survival
Therapeutics
Leukopenia
Peripheral Nervous System Diseases
Progesterone Receptors
Adjuvant Chemotherapy
Neutropenia
Microtubules
human ERBB2 protein

Keywords

  • Eribulin
  • HER2-negative breast cancer
  • Metastatic breast cancer
  • Progression-free survival
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. / McIntyre, Kristi; O'Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak, Erhan; Song, James X.; Cox, David; Vahdat, Linda T.

In: Breast Cancer Research and Treatment, Vol. 146, No. 2, 01.01.2014, p. 321-328.

Research output: Contribution to journalArticle

McIntyre, Kristi ; O'Shaughnessy, Joyce ; Schwartzberg, Lee ; Glück, Stefan ; Berrak, Erhan ; Song, James X. ; Cox, David ; Vahdat, Linda T. / Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. In: Breast Cancer Research and Treatment. 2014 ; Vol. 146, No. 2. pp. 321-328.
@article{769e621d80c6473eaca0e0f5f62c452e,
title = "Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer",
abstract = "Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This phase 2 study evaluated efficacy and safety of eribulin as first-line therapy for human epidermal growth factor receptor 2-negative (HER2-negative) MBC. Patients with measurable HER2-negative locally recurrent breast cancer or MBC with ≥12 months since prior neoadjuvant or adjuvant (neo/adjuvant) chemotherapy received eribulin mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week cycle. Endpoints included objective response rate (ORR) per RECIST v1.1 (primary), safety, progression-free survival (PFS), clinical benefit rate (ORR + stable disease ≥6 months; CBR), and duration of response (DOR). Fifty-six patients were enrolled and received eribulin; 38 (68 {\%}) had prior neo/adjuvant therapy, including 33 who had anthracycline and/or taxane-containing chemotherapy; 41 (73 {\%}) had estrogen receptor-positive disease, and 12 (21 {\%}) had estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) disease. Patients received a median of 7 cycles (range 1-43); 6 (11 {\%}) received treatment for ≥12 months. ORR was 29 {\%} (95 {\%} CI 17.3-42.2), CBR was 52 {\%}, and median DOR was 5.8 months. Median PFS was 6.8 months. Thirty-six patients (64 {\%}) had grade 3/4 treatment-related adverse events; most common were neutropenia (50 {\%}), leukopenia (21 {\%}), and peripheral neuropathy (21 {\%}). These results demonstrate that eribulin has substantial antitumor activity as first-line treatment for HER2-negative MBC with acceptable safety.",
keywords = "Eribulin, HER2-negative breast cancer, Metastatic breast cancer, Progression-free survival, Triple-negative breast cancer",
author = "Kristi McIntyre and Joyce O'Shaughnessy and Lee Schwartzberg and Stefan Gl{\"u}ck and Erhan Berrak and Song, {James X.} and David Cox and Vahdat, {Linda T.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10549-014-2923-9",
language = "English",
volume = "146",
pages = "321--328",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

AU - McIntyre, Kristi

AU - O'Shaughnessy, Joyce

AU - Schwartzberg, Lee

AU - Glück, Stefan

AU - Berrak, Erhan

AU - Song, James X.

AU - Cox, David

AU - Vahdat, Linda T.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This phase 2 study evaluated efficacy and safety of eribulin as first-line therapy for human epidermal growth factor receptor 2-negative (HER2-negative) MBC. Patients with measurable HER2-negative locally recurrent breast cancer or MBC with ≥12 months since prior neoadjuvant or adjuvant (neo/adjuvant) chemotherapy received eribulin mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week cycle. Endpoints included objective response rate (ORR) per RECIST v1.1 (primary), safety, progression-free survival (PFS), clinical benefit rate (ORR + stable disease ≥6 months; CBR), and duration of response (DOR). Fifty-six patients were enrolled and received eribulin; 38 (68 %) had prior neo/adjuvant therapy, including 33 who had anthracycline and/or taxane-containing chemotherapy; 41 (73 %) had estrogen receptor-positive disease, and 12 (21 %) had estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) disease. Patients received a median of 7 cycles (range 1-43); 6 (11 %) received treatment for ≥12 months. ORR was 29 % (95 % CI 17.3-42.2), CBR was 52 %, and median DOR was 5.8 months. Median PFS was 6.8 months. Thirty-six patients (64 %) had grade 3/4 treatment-related adverse events; most common were neutropenia (50 %), leukopenia (21 %), and peripheral neuropathy (21 %). These results demonstrate that eribulin has substantial antitumor activity as first-line treatment for HER2-negative MBC with acceptable safety.

AB - Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This phase 2 study evaluated efficacy and safety of eribulin as first-line therapy for human epidermal growth factor receptor 2-negative (HER2-negative) MBC. Patients with measurable HER2-negative locally recurrent breast cancer or MBC with ≥12 months since prior neoadjuvant or adjuvant (neo/adjuvant) chemotherapy received eribulin mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week cycle. Endpoints included objective response rate (ORR) per RECIST v1.1 (primary), safety, progression-free survival (PFS), clinical benefit rate (ORR + stable disease ≥6 months; CBR), and duration of response (DOR). Fifty-six patients were enrolled and received eribulin; 38 (68 %) had prior neo/adjuvant therapy, including 33 who had anthracycline and/or taxane-containing chemotherapy; 41 (73 %) had estrogen receptor-positive disease, and 12 (21 %) had estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) disease. Patients received a median of 7 cycles (range 1-43); 6 (11 %) received treatment for ≥12 months. ORR was 29 % (95 % CI 17.3-42.2), CBR was 52 %, and median DOR was 5.8 months. Median PFS was 6.8 months. Thirty-six patients (64 %) had grade 3/4 treatment-related adverse events; most common were neutropenia (50 %), leukopenia (21 %), and peripheral neuropathy (21 %). These results demonstrate that eribulin has substantial antitumor activity as first-line treatment for HER2-negative MBC with acceptable safety.

KW - Eribulin

KW - HER2-negative breast cancer

KW - Metastatic breast cancer

KW - Progression-free survival

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84904117817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904117817&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-2923-9

DO - 10.1007/s10549-014-2923-9

M3 - Article

C2 - 24699910

AN - SCOPUS:84904117817

VL - 146

SP - 321

EP - 328

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -